Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) largest independent shareholder, Jorey Chernett, delivered a letter on April 6, 2026 calling for an immediate, comprehensive review of strategic alternatives, including a potential sale of the Company's TMS business.

The letter cites a 14.12% ownership stake, argues that post-acquisition synergies have not materialized since December 2024, and claims applying comparable multiples implies 5–7x upside to current STIM equity value. Chernett urges the Board to engage advisors to evaluate all options and consider separating the clinic business as a standalone.

Positive

• 14.12% stake held by largest independent shareholder
• Calls for comprehensive strategic review including sale option
• Claims potential 5–7x implied equity value

Negative

• Post-acquisition synergies have not materialized since December 2024
• Peers have materially outperformed STIM after the acquisition
• Company operates two structurally distinct businesses with finite resources

News Market Reaction – STIM

-10.23%

57 alerts

-10.23% Session close to close

+34.2% Peak Tracked

-6.0% Trough Tracked

$125.74M Market Cap

1.1x Rel. Volume

In the Apr 7 session, STIM declined 10.23%, reflecting a significant negative market reaction. Argus tracked a peak move of +34.2% during that session. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 57 alerts that day, indicating high trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.2% in the session following this news. A negative reaction despite calls for a...

Analysis

The stock dropped -10.2% in the session following this news. A negative reaction despite calls for a strategic review could fit the stock’s history of volatile responses to news. While the largest independent holder, with 14.12% of shares, outlined potential 5–7x upside from separating the TMS and clinic operations, investors may focus on execution risks or uncertainty around outcomes. The existing shelf registration for 20,737,061 resalable shares also underscores potential selling pressure if sentiment weakens further.

Key Figures

Shareholder stake: 14.12% of outstanding shares Implied upside: 5–7x current price Acquisition timing: December 2024 +2 more

5 metrics

Shareholder stake 14.12% of outstanding shares Ownership reported by Jorey Chernett in the article

Implied upside 5–7x current price Upside potential cited in shareholder letter for STIM equity value

Acquisition timing December 2024 Reference point for the Greenbrook acquisition under discussion

Peer performance Pure-play peers outperformed Peers noted as trading at substantially higher multiples post-acquisition

Business count Two distinct businesses TMS business and standalone clinic business identified as separate assets

Historical Context

5 past events · Latest: Mar 17 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 17	Q4/FY25 earnings	Negative	-9.9%	Reported strong revenue growth but lower margins and a significant net loss.
Mar 17	CEO appointment	Positive	-9.9%	Named new President and CEO with sizeable RSU grant and device experience.
Mar 03	Earnings date set	Neutral	-1.6%	Announced timing and access details for upcoming Q4 2025 earnings release.
Feb 10	Prelim results	Positive	+23.3%	Prelim Q4/FY25 results showed strong revenue growth and positive operating cash flow.
Nov 20	Conference appearance	Neutral	-12.8%	Planned participation in a major healthcare conference fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has produced mixed reactions: strong fundamental updates sometimes lifted shares sharply, while earnings and leadership news also saw notable selloffs.

Recent Company History

Over the past several months, Neuronetics has focused on growth and integration. Earnings updates in February–March 2026 highlighted rapid revenue expansion, largely from the December 2024 Greenbrook acquisition, but also ongoing net losses. Preliminary results on Feb 10, 2026 were followed by a strong positive move, while the full Q4/FY2025 report on Mar 17, 2026 coincided with a double-digit decline. Leadership changes, including appointing a new CEO effective Mar 23, 2026, and conference participation in Nov 2025 also saw negative reactions, underscoring volatile sentiment around strategic developments.

Key Terms

strategic alternatives, tms, tam, micro-cap

4 terms

strategic alternatives financial

"calling for the immediate initiation of a comprehensive review of strategic alternatives"

Strategic alternatives are different options a company considers to improve its value or achieve its goals, such as selling the business, merging with another company, or restructuring operations. For investors, understanding these options is important because they can significantly impact the company's future direction and its stock value, often signaling potential changes or opportunities.

tms medical

"including the potential sale of the Company's TMS business"

Transcranial magnetic stimulation is a noninvasive medical treatment that uses brief magnetic pulses to stimulate specific areas of the brain, similar to tapping a circuit to reset its activity. Investors watch TMS because approvals, clinical trial results, or wider insurance coverage can open large markets for devices and services, affecting revenue and growth prospects for companies developing or delivering the therapy.

tam financial

"two compelling, high-quality assets with large and expanding TAMs"

Total addressable market (TAM) is an estimate of the total revenue opportunity available for a product or service if it captured every possible customer. Think of it as the size of the whole pie a business could potentially eat from; investors use it to judge how large a company could grow, whether current sales are a small slice or a meaningful portion, and to compare growth opportunities across industries.

micro-cap financial

"A micro-cap enterprise with finite resources cannot effectively serve two structurally distinct businesses."

A micro-cap is a publicly traded company with a very small total market value, generally measured as market capitalization and often considered to be below roughly $300 million (thresholds can vary). For investors it matters because these stocks can offer outsized gains but also carry higher risk: they tend to have fewer buyers and sellers, wider price swings, and less public information—think of a tiny neighborhood shop that can grow fast or fail suddenly compared with a big supermarket.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business

BLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") owning approximately 14.12% of outstanding shares, today delivered a letter to the STIM Board of Directors (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Company's TMS business.

The letter outlines the substantial value that could be delivered to shareholders if a sale of the TMS business were to be executed and the clinic business was to operate on a standalone basis. Specifically:

• STIM has two compelling, high-quality assets with large and expanding TAMs, market-leading positions, accelerating adoption, and meaningful industry tailwinds.
• Despite these attractive businesses, the anticipated synergies of combining TMS and Greenbrook have not materialized, and the premise of 1 + 1 > 3 has proven illusory.
• Since the December 2024 acquisition, pure-play peers have dramatically outperformed STIM and now trade at substantially higher multiples.
• A micro-cap enterprise with finite resources cannot effectively serve two structurally distinct businesses.
• Applying conservative, yet comparable multiples to STIM's constituent businesses implies equity value to shareholders of 5–7x the current price of STIM's stock.
• Further upside could be present with effective oversight and full dedication of resources to the industry leading clinic business. 
• The Board must act in the best interest of STIM shareholders and immediately engage qualified advisors to evaluate all strategic alternatives.

The full text of the letter can be found here:

Media Contact:
ASC Advisors
Taylor Ingraham / Max Rayden
tingraham@ascadvisors.com / mrayden@ascadvisors.com
203 992 1230

View original content to download multimedia:https://www.prnewswire.com/news-releases/largest-independent-shareholder-of-neuronetics-inc-jorey-chernett-calls-for-immediate-and-comprehensive-review-of-strategic-alternatives-including-sale-of-tms-business-302734977.html

SOURCE Jorey Chernett

FAQ

What did Jorey Chernett request from the Neuronetics (STIM) board on April 6, 2026?

He requested an immediate, comprehensive review of strategic alternatives, including sale of the TMS business. According to Jorey Chernett, the Board should engage qualified advisors to evaluate all options and consider separating the clinic business as a standalone.

How much of Neuronetics (STIM) does Jorey Chernett own, according to the April 6, 2026 letter?

Chernett owns approximately 14.12% of outstanding Neuronetics shares. According to Jorey Chernett, that stake is cited to justify pressing the Board for an advisor-led strategic review and possible divestiture of the TMS business.

What valuation upside did the April 6, 2026 letter claim for Neuronetics (STIM)?

The letter claims applying comparable multiples implies equity value of about 5–7x the current STIM price. According to Jorey Chernett, that upside assumes a sale of the TMS business and standalone operation of the clinic business.

Why does the April 6, 2026 letter say Neuronetics (STIM) should consider selling the TMS business?

The letter argues synergies between TMS and Greenbrook have not materialized, and a micro-cap cannot serve two distinct businesses effectively. According to Jorey Chernett, separation could unlock shareholder value and improve operational focus.

What timeline or prior transactions does the April 6, 2026 letter reference for Neuronetics (STIM)?

The letter references the December 2024 acquisition as the point after which expected synergies failed to appear. According to Jorey Chernett, peers outperformed STIM following that acquisition, motivating the call for a strategic review.

What specific actions did Jorey Chernett ask the Neuronetics (STIM) board to take immediately?

He asked the Board to immediately engage qualified advisors to evaluate all strategic alternatives, including a sale of the TMS business. According to Jorey Chernett, prompt advisor engagement is needed to assess options and pursue shareholder value.